Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

Hiroyuki Kitao, Kazuaki Matsuoka, Makoto Iimori, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki, Yuji Miyamoto, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalReview article

Abstract

Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume43
Issue number1
Publication statusPublished - Jan 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)'. Together they form a unique fingerprint.

  • Cite this